Immunovant Ratios and Metrics

Market cap in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jul '26 Jul 2, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Market Cap	7,964	5,066	2,907	4,704	2,021	642
Market Cap Growth	204.33%	74.25%	-38.19%	132.70%	214.95%	-59.16%
Enterprise Value	7,062	4,164	2,193	4,069	1,646	150.37
Last Close Price	38.79	24.84	17.09	32.31	15.51	5.51
PB Ratio	9.28	5.94	4.11	7.61	5.58	1.37
P/TBV Ratio	8.30	5.32	3.66	7.22	5.27	1.29
Debt / Equity Ratio	-	0	0	0	0.00	0.00
Net Debt / Equity Ratio	-1.06	-1.06	-1.01	-1.03	-1.03	-1.05
Net Debt / EBITDA Ratio	1.69	1.69	1.63	2.25	1.72	3.15
Net Debt / FCF Ratio	2.22	2.22	1.90	2.96	1.99	4.62
Quick Ratio	8.65	8.65	10.41	13.18	8.71	11.37
Current Ratio	9.09	9.09	11.16	13.70	9.34	11.52
Return on Equity (ROE)	-55.00%	-64.82%	-62.46%	-52.91%	-50.69%	-36.39%
Return on Assets (ROA)	-53.06%	-61.52%	-60.88%	-52.85%	-47.38%	-33.61%
Return on Capital Employed (ROCE)	-57.96%	-68.32%	-66.13%	-57.68%	-52.37%	-36.09%
Buyback Yield / Dilution	-20.35%	-20.35%	-9.76%	-12.21%	-12.21%	-24.98%
Total Shareholder Return	-20.35%	-20.35%	-9.76%	-12.21%	-12.21%	-24.98%

SEC Filings: 10-K · 10-Q